Phase-change contrast agents (PCCAs) are an innovative form of imaging agent with practical applications in both the research and clinical settings. PCCAs are derived from gaseous microbubbles, which are able to act as targeted-contrast agents through conjugation of a ligand that is selective for an overexpressed receptor or biomarker in a given disease. Gaseous microbubbles can be condensed to liquid phase nanodroplets, which should be sufficiently small to extravasate into cells and/or tissues given their size and stability. Once liquid nanodroplets have internalized within a given tissue, they can be "activated" back into gaseous microbubbles with ultrasound at clinically used frequencies and energy outputs. This is purposeful as microbubbles provide much greater ultrasound reflectivity than nanodroplets. In this study, PCCAs and/or microbubbles act as a targeting agent in multiple scenarios. The projects in this study include- examination of binding and internalization of targeted PCCAs with different gaseous cores within MDA-MB-231 breast cancer cells, vaporization of liquid phase nanodroplets through application of acoustic energy via focused ultrasound (FUS), and targeting vulnerable plaque in the heart with different types of targeted microbubbles under varying shear-stresses.

Acoustic droplet vaporization (ADV) is a process in which a phase shift of a liquified droplet into a gaseous microbubble, is triggered using an ultrasonic wave. In contrast to utilizing conventional contrast agents in ultrasound, the phase change contrast agents used in ADV can extravasate into tumor tissue, and they offer a greater circulatory lifespan, thereby increasing the potential applications in which they can be utilized. In this project, the impact of different ultrasound parameters on the efficiency of ADV was investigated, using a programmable ultrasound system. Two different ultrasound sequences were designed, for imaging and vaporization of droplets. Furthermore, three different sets of experiments were performed. Firstly, the vaporization effect of different imaging voltages was investigated, whereby a setting of 15V was identified as an able voltage for the remaining experiments. Secondly, experiments concerning the effect of vaporizing frequency on the ADV efficiency were performed, including the use of single and dual frequencies. Lastly, different frequency settings were combined with varying the number of cycles, to assess how the choice of pulse length influences the vaporization. The results from the project indicate that no substantial difference in ADV efficiency is achieved when using different frequency settings for perfluoropentane droplets encapsulated by cellulose nanofibers. However, the results provide clear indications of the benefit of using longer pulse durations on the vaporization efficiency. In conclusion, further studies are required before ADV can be translated into a clinical setting.

Ultrasound-mediated drug delivery has been proposed as a safe and non-invasive method to achieve localized drug release. Drug-loaded microbubbles are injected in the vascular system and ultrasound waves are then used to localize and burst the microbubbles at a specific targeted area. The relatively large size of microbubbles however limits both their lifetime and their reach in the human body. Phase-change liquid droplets can extend the use of ultrasound contrast agents for localized drug delivery. Their smaller size provides several advantages. The droplets can reach smaller capillaries, such as those in tumors vasculature. Their lifetime is also considerably prolonged. Through the phenomenon of Acoustic Droplet Vaporization (ADV), triggered by ultrasound stimulation, the liquid-filled droplets experience a phase change and are converted into gas-filled microbubbles. The newly created microbubbles can then be disrupted by further stimulation and release their drug load in the tumor tissue. In this project, a protocol to image and burst perfluoropentane-based micro-sized droplets using a single transducer is developed using the Verasonics Ultrasound System. The pulse sequences are developed to allow close monitoring of the drug delivery by capturing a series of images before and after the vaporization or destruction of the droplets. The droplets response was assessed for different pulse voltages and durations. Mean pixel value was calculated for the regions of interest, using the images captured before and after delivery of the ultrasound pulse. Vaporization of the droplets can be achieved with low voltage (10V), whereas high voltage (50V) triggers their destruction. Combined with high voltage, pulse duration affects the rate at which droplets can be destructed.